Endowment Wealth Management Inc. Has $526,000 Stock Position in Humacyte, Inc. (NASDAQ:HUMA)

Endowment Wealth Management Inc. boosted its position in Humacyte, Inc. (NASDAQ:HUMA) by 3.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 104,108 shares of the company’s stock after buying an additional 3,590 shares during the quarter. Endowment Wealth Management Inc.’s holdings in Humacyte were worth $526,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. State Street Corp increased its holdings in Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after buying an additional 1,895,529 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Humacyte by 9.6% in the third quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock valued at $11,101,000 after buying an additional 179,120 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Humacyte by 7.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 775,718 shares of the company’s stock valued at $3,917,000 after buying an additional 54,400 shares in the last quarter. Private Advisor Group LLC raised its position in Humacyte by 60.7% during the fourth quarter. Private Advisor Group LLC now owns 599,700 shares of the company’s stock valued at $3,028,000 after purchasing an additional 226,590 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in Humacyte by 30.9% during the third quarter. Wellington Management Group LLP now owns 254,411 shares of the company’s stock valued at $1,384,000 after purchasing an additional 60,087 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Wall Street Analysts Forecast Growth

HUMA has been the topic of several analyst reports. Benchmark reissued a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Friday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Price Performance

Shares of HUMA stock opened at $2.90 on Tuesday. The company has a market capitalization of $364.99 million, a P/E ratio of -2.16 and a beta of 1.36. The company’s 50-day simple moving average is $4.13 and its two-hundred day simple moving average is $4.80. Humacyte, Inc. has a one year low of $2.81 and a one year high of $9.97.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.